Hypercholesterolemia: Clinical Trials

865 completed, 82 unknown, 61 terminated, 47 recruiting. 309 Not applicable, 275 Phase 3, 148 Phase 4, 145 Phase 2, 105 Phase 1.

By phase and status

Phase	Trials	Status
Not applicable	309	Completed 213, Unknown 38, Recruiting 16, Active not recruiting 12, Terminated 12, Not yet recruiting 7, Withdrawn 7, Enrolling by invitation 3, Suspended 1
Phase 3	275	Completed 229, Terminated 22, Recruiting 9, Active not recruiting 5, Unknown 4, Enrolling by invitation 2, Not yet recruiting 2, Withdrawn 2
Phase 4	148	Completed 109, Unknown 17, Terminated 9, Recruiting 4, Withdrawn 4, Not yet recruiting 3, Active not recruiting 2
Phase 2	145	Completed 122, Terminated 6, Not yet recruiting 5, Recruiting 5, Unknown 4, Withdrawn 2, Active not recruiting 1
Phase 1	105	Completed 86, Terminated 7, Recruiting 4, Unknown 4, Withdrawn 2, Enrolling by invitation 1, Not yet recruiting 1
Early Phase 1	8	Completed 7, Not yet recruiting 1

Follow Hypercholesterolemia: new trials by email Literature Review of Hypercholesterolemia trials Research Report on Hypercholesterolemia

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma Evolocumab, Routine Lipid Management, Autoinjector - Coronary Artery Disease, Hypercholesterolemia	Phase 4	Not yet recruiting	Amgen	308	2027-01-31	2026-09-21
RCT for the Chinese Medicine in Treating Hypercholesterolemia Dachaihu Decoction combined Erzhiwan with variation, Placebo granules - Hypercholesterolemia	Phase 2	Not yet recruiting	Chinese University of Hong Kong	70	2027-01-01	2026-07-30
An Observational Study to Evaluate Treatment Patterns in High, Very High and Extreme Cardiovascular Risk Patients With Hypercholesterolemia, Including Familial Hypercholesterolemia Hypercholesterolaemia, Familial Hypercholesterolaemia		Not yet recruiting	Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)	2500	2027-01-01	2026-11-03
Lipid Management Gaps in Mexican Patients at High and Very High Cardiovascular Risk Lipid-Lowering Therapy in Routine Clinical Practice - Dyslipidemias, Hypercholesterolemia		Not yet recruiting	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	1600	2027-01-01	2026-11-12
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients Laroprovstat, Rosuvastatin 1, Rosuvastatin 2 - Hypercholesterolemia	Phase 3	Not yet recruiting	AstraZeneca	204	2026-12-21	2026-11-12
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C) Drug: EDIT-401, Placebo - Heterozygous Familial Hypercholesterolemia (HeFH)	Phase 1 / Phase 2	Not yet recruiting	Editas Medicine, Inc.	56	2026-11-01	2026-10-26
Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease Dose adjustment of statins, no dose adjustment - Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia, Stroke (CVA) or TIA	Phase 4	Not yet recruiting	Rehman Medical Institute - RMI	178	2026-11-01	2026-11-05
Metabolic Effects of an Ophiocordyceps Sinensis- and CoQ10-Based Formulation in Mild-to-Moderate Hypercholesterolemia CORDICOL, Placebo - Hypercholesterolemia, Lipid Metabolism Disorders	Not applicable	Not yet recruiting	noiVita Srls	140	2026-10-19	2026-10-08
A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038) Enlicitide Decanoate, Placebo - Hyperlipidemia, Hypercholesterolemia	Phase 3	Recruiting	Merck Sharp & Dohme LLC	150	2026-10-15	2026-11-02
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events Bempedoic acid, Ezetimibe, Rosuvastatin - Coronary Atherosclerosis, Mixed Dyslipidemia	Phase 3	Not yet recruiting	Daiichi Sankyo	103	2026-09-30	2026-09-29
A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease VERVE-102, Placebo - Atherosclerosis, Cardiovascular Disease	Phase 2	Recruiting	Verve Therapeutics, Inc.	175	2026-09-24	2026-11-10
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia laroprovstat/rosuvastatin 1, laroprovstat/rosuvastatin 2, laroprovstat/rosuvastatin 3 - Hypercholesterolaemia	Phase 3	Recruiting	AstraZeneca	200	2026-09-10	2026-10-05
Berberol P for Mild-to-Moderate Hypercholesterolaemia Berberol® P (manufacturer: PharmExtracta S.p.A.), Berberol® K (manufacturer: PharmExtracta S.p.A.) - Hypercholesterolemia	Not applicable	Not yet recruiting	Liaquat University of Medical & Health Sciences	255	2026-09-07	2026-08-27
Electronic Letters to Improve Patient Activation in IHD: The NUDGE-IHD Trial LDL-C information letter, Lp(a) information letter - Ischemic Heart Disease, Coronary Artery Disease	Not applicable	Not yet recruiting	Tor Biering-Sørensen	123000	2026-09-01	2026-09-08
Long-Term Cardiovascular Impact of ArmoLIPID Cholesterol Plus: An In Silico Study Using Digital Twins Hypercholesterolemia, Cardiovascular Risk		Completed	Aeterna Medical Solutions SL	100000	2026-09-01	2026-10-28
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. Laroprovstat, Rosuvastatin 1, Rosuvastatin 2 - Hypercholesterolaemia	Phase 3	Recruiting	AstraZeneca	600	2026-08-12	2026-09-10
Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH lerodalcibep 300 mg Monthly SC - Familial Hypercholesterolemia - Heterozygous	Phase 3	Enrolling by invitation	LIB Therapeutics LLC	150	2026-07-20	2026-07-28
A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to Statins Pemafibrate 0.2 mg/day, Pemafibrate 0.4 mg/day, Placebo - Hypercholesterolemia	Phase 4	Recruiting	Kowa Company, Ltd.	120	2026-07-01	2026-07-13
Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study Colesevelam, Placebo - PFAS, Environmental Exposures	Phase 2	Not yet recruiting	University of Rhode Island	50	2026-07-01	2026-05-18
A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C) STX-1150 - Elevated LDL-C and High Cholesterol	Phase 1	Recruiting	Monash University	64	2026-06-30	2026-09-21

Showing 20 of 1135. Sign in to see all of them.

Narrower conditions

Dyslipidemias (142)  ·  Hyperlipidemias (140)  ·  Hypertension (139)  ·  Cardiovascular Diseases (130)  ·  Diabetes Mellitus (100)  ·  Atherosclerosis (83)  ·  Obesity (72)  ·  Hyperlipoproteinemia Type II (58)  ·  Coronary Disease (54)  ·  Diabetes Mellitus, Type 2 (39)  ·  Coronary Artery Disease (38)  ·  Heart Diseases (37)  ·  Hypertriglyceridemia (34)  ·  Metabolic Syndrome (32)

Broader conditions

Nutritional and Metabolic Diseases (1133)  ·  Metabolic Diseases (1114)  ·  Lipid Metabolism Disorders (1111)  ·  Hyperlipidemias (995)  ·  Dyslipidemias (993)  ·  Vascular Diseases (285)  ·  Cardiovascular Diseases (232)  ·  Glucose Metabolism Disorders (171)  ·  Pathological Conditions, Signs and Symptoms (153)  ·  Endocrine System Diseases (140)  ·  Arterial Occlusive Diseases (122)  ·  Arteriosclerosis (120)  ·  Signs and Symptoms (102)  ·  Myocardial Ischemia (100)  ·  Heart Diseases (97)

Interventions

Ezetimibe (154)  ·  Atorvastatin (134)  ·  Rosuvastatin Calcium (87)  ·  Simvastatin (84)  ·  alirocumab (49)  ·  evolocumab (43)  ·  8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (25)  ·  Hydroxymethylglutaryl-CoA Reductase Inhibitors (25)  ·  Pravastatin (23)  ·  Ezetimibe, Simvastatin Drug Combination (22)  ·  pitavastatin (21)  ·  ALN-PCS (20)  ·  Niacin (16)  ·  1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid (15)  ·  Phytosterols (15)

Sponsors

Organon and Co (87)  ·  AstraZeneca (60)  ·  Sanofi (37)  ·  Amgen (35)  ·  National Heart, Lung, and Blood Institute (NHLBI) (30)  ·  Merck Sharp & Dohme LLC (27)  ·  Novartis Pharmaceuticals (23)  ·  Pfizer (17)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (17)  ·  Esperion Therapeutics, Inc. (15)  ·  Takeda (15)  ·  Regeneron Pharmaceuticals (12)  ·  University of Bologna (11)  ·  Kastle Therapeutics, LLC (10)  ·  Raisio Group (9)

Countries

United States (378)  ·  Canada (123)  ·  Germany (81)  ·  Italy (81)  ·  Netherlands (81)  ·  Spain (78)  ·  United Kingdom (78)  ·  South Korea (69)  ·  France (64)  ·  China (53)  ·  Japan (52)  ·  Australia (51)  ·  Denmark (50)  ·  South Africa (50)  ·  Czechia (48)

Top investigators

Russell Esterline (8)  ·  Ron Haberman, MD (7)  ·  Claudio Borghi, MD (4)  ·  Dragos Budinski, Med Dr. (4)  ·  Evan A Stein, MD PhD (4)  ·  Peter Jones, PhD (4)

Results publications

PMID 30183102, PMID 21518985, PMID 33078867, PMID 27777279, PMID 34298554, PMID 37994400, PMID 28181260, PMID 28964736, PMID 32609313, PMID 35916348, PMID 25614280, PMID 26872608, PMID 27578134, PMID 28391886, PMID 29037448, PMID 38018702, PMID 38063346, PMID 38757725, PMID 41604274, PMID 10205010, PMID 20573639, PMID 20663203, PMID 20707601, PMID 22087637, PMID 24014831, PMID 25060413, PMID 25269777, PMID 25431239, PMID 25773607, PMID 26892399, PMID 27184170, PMID 32187462, PMID 33380172, PMID 33990512, PMID 37282500, PMID 37565307, PMID 40587053, PMID 41903707, PMID 10593347, PMID 11282049, PMID 11781675, PMID 11975899, PMID 12359975, PMID 12485966, PMID 12620529, PMID 12719279, PMID 12719282, PMID 12917318, PMID 14736433, PMID 15311720

NIH funding

2015 (11), 2005 (8), 2017 (5), 2025 (4), 2014 (3), 2016 (3), 2023 (3), OT2HL158287 (3), 2004 (2), K23GM100372 (2), P01HS021141 (2), R01HL050420 (2), 2008 (1), 2009 (1), 2019 (1)